Myocet

Phase 3Small molecule

Roche

Myocet is one of 57 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoblastic LeukemiaActive, not recruiting

Breast CancerActive, not recruiting

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Myocet

Roche

Phase 3

3 3

Zolymbus

AbbVie

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Zinecard

CChildren's Oncology Group

Preclinical

2 7

Acupan

YYonsei University

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Aquasol E

NNational Eye Institute (NEI)

Paracetamol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Acute Lymphoblastic Leukemia

NCT03643276

Clinical

Trials by Indication[1]

Breast Cancer3 trials

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 1/2·NCT02015676·69 enrolled

Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 1/2·NCT00129896·73 enrolled

Trial of Myocet in Metastatic Breast Cancer

Unknown status·SSopherion Therapeutics·Phase 3·NCT00294996·363 enrolled

Acute Lymphoblastic Leukemia1 trial

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Recruiting·MMartin Schrappe·Phase 3·NCT03643276·5,000 enrolled

Elderly Patients1 trial

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

Completed·WWest German Study Group·Phase 3·NCT02214381·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Myocet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Myocet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Myocet. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Myocet

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Breast Cancer3 trials

Acute Lymphoblastic Leukemia1 trial

Elderly Patients1 trial

References

Drug Info

Quick Facts

Related News